Treatment of malignant melanoma by high-peak-power 1064 nm irradiation followed by photodynamic therapy.
Irradiation of B16 pigmented melanoma subcutaneously transplanted in C57 mice with a single 650 mJ pulse (10 ns) of 1064 nm light from a Q-switched Nd: YAG laser caused instantaneous bleaching of the pigmented tissue. Visual and histological examination of the resulting gray-colored tumor revealed the breakdown of melanosomes with no detectable alteration of the normal and tumor-overlying skin. Histological examination of the irradiated tumor showed some degree of vascular damage; the depth of the photodamage was not affected by the successive delivery of three consecutive light pulses. The bleached tumor grew at a modestly slower rate but the high-peak-power (HPP) laser treatment did not affect the tumor concentration of a photodynamic sensitizer Si(i.v.)-naphthalocyanine (isoBO-SiNc) intravenously injected 24 h before Nd:YAG irradiation. Treatment of the B16 pigmented melanoma by photodynamic therapy (PDT: 1 mg/kg isoBO-SiNc, 300 mW/cm2, 520 J/cm2) from a 774 nm diode laser immediately after the 1064 nm irradiation resulted in a 16 day delay of tumor regrowth, which was markedly longer than the delay (ca 6 days) obtained after PDT under identical conditions without the preirradiation. Thus, pretreatment of pigmented tumors with HPP 1064 nm light appears to enhance their susceptibility to conventional PDT. The tumor response was further enhanced by repeating the combined HPP/PDT treatment at an interval of 10 days (regrowth delay: 27 days), as well as by applying hyperthermia immediately after HPP/PDT (regrowth delay: ca 34 days).
Busetti
A
A
Department of Biology, University of Padova, Italy. polo@civ.bio.unipd.it
Soncin
M
M
Jori
G
G
Kenney
M E
ME
Rodgers
M A
MA
D000818:Animals; D003131:Combined Modality Therapy; D004337:Drug Carriers; D005260:Female; D053685:Laser Therapy; D008081:Liposomes; D008546:Melanoma, Experimental / Q000188:drug therapy* / Q000473:pathology / Q000532:radiotherapy*; D008665:Metalloporphyrins / Q000008:administration & dosage / Q000627:therapeutic use*; D051379:Mice; D008807:Mice, Inbred BALB C; D008810:Mice, Inbred C57BL; D017646:Organosilicon Compounds / Q000008:administration & dosage / Q000627:therapeutic use*; D010778:Photochemotherapy; D011838:Radiation-Sensitizing Agents / Q000627:therapeutic use*
D004337:Drug Carriers; D008081:Liposomes; D008665:Metalloporphyrins; D017646:Organosilicon Compounds; D011838:Radiation-Sensitizing Agents; C072758:bis(di-isobutyloctadecylsiloxy)silicon 2,3-naphthalocyanine